Camille Tron

Dr. Camille Tron

Inserm, EHESP, institut de recherche en santé, environnement et travail (Irset) - UMRS 1085, université Rennes, CHU Rennes, 35000 Rennes, France; Inserm, centre d'investigation clinique 1414, 35000 Rennes, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2018 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
CTCamille Tron
Camille Tron
FLFlorian Lemaitre
Florian Lemaitre
CVCéline Verstuyft
Céline Verstuyft
APAntoine Petitcollin
Antoine Petitcollin
MVMarie-Clémence Verdier
Marie-Clémence Verdier
EBEric Bellissant
Eric Bellissant

12 March 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CTCamille Tron
Camille Tron
JWJean-Baptiste Woillard
Jean-Baptiste Woillard
PHPauline Houssel-Debry
Pauline Houssel-Debry
VDVéronique David
Véronique David
CJCaroline Jezequel
Caroline Jezequel
FLFlorian Lemaitre
Florian Lemaitre
Tacrolimus (TAC) is the cornerstone of immunosuppressive therapy in liver transplantation. This study aimed at elucidating the interplay between pharmacogenetic determinants of TAC whole blood and intracellular exposures as well as the pharmacokinetic-pharmacodynamic relationship of TAC in both compartments. Complete pharmacokinetic profiles (Predose, and 20 min, 40 min, 1h, 2h, 3h, 4h, 6h, 8h, 12h post drug intake) of twice daily TAC in whole blood and peripheral blood mononuclear cells (PBMC) were collected in 32 liver transplanted patients in the first ten days post transplantation. A non-parametric population pharmacokinetic model was applied to explore TAC pharmacokinetics in blood and PBMC. Concurrently, calcineurin activity was measured in PBMC. Influence of donor and recipient genetic polymorphisms of ABCB1, CYP3A4 and CYP3A5 on TAC exposure was assessed. Recipient ABCB1 polymorphisms 1199G>A could influence TAC whole blood and intracellular exposure (p<0.05). No association was found between CYP3A4 or CYP3A5 genotypes and TAC whole blood or intracellular concentrations. Finally, intra-PBMC calcineurin activity appeared incompletely inhibited by TAC and less than 50% of patients were expected to achieve intracellular IC50 concentration (100 pg/millions of cells) at therapeutic whole blood concentration (i.e.: 4–10 ng/mL). Together, these data suggest that personalized medicine regarding TAC therapy might be optimized by ABCB1 pharmacogenetic biomarkers and by monitoring intracellular concentration whereas the relationship between intracellular TAC exposure and pharmacodynamics biomarkers more specific than calcineurin activity should be further investigated.

1 February 2021 in Journal of Chromatography B
Verified
Journal Article
Closed access
CTCamille Tron
Camille Tron
MFMarie-José Ferrand-Sorre
Marie-José Ferrand-Sorre
JQJulie Querzerho-Raguideau
Julie Querzerho-Raguideau
JCJonathan M. Chemouny
Jonathan M. Chemouny
PHPauline Houssel-Debry
Pauline Houssel-Debry
FLFlorian Lemaitre
Florian Lemaitre

11 September 2018 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
CTCamille Tron
Camille Tron
MAMarie Allard
Marie Allard
APAntoine Petitcollin
Antoine Petitcollin
MFMarie‐José Ferrand‐Sorre
Marie‐José Ferrand‐Sorre
MVMarie‐Clémence Verdier
Marie‐Clémence Verdier
FLFlorian Lemaitre
Florian Lemaitre

1 December 2016 in Journal of Chromatography A
Verified
Journal Article
Closed access
CTCamille Tron
Camille Tron
MRMichel Rayar
Michel Rayar
APAntoine Petitcollin
Antoine Petitcollin
JBJean-Marie Beaurepaire
Jean-Marie Beaurepaire
CCCaterina Cusumano
Caterina Cusumano
FLFlorian Lemaitre
Florian Lemaitre

23 June 2022 in Bioanalysis
Verified
Journal Article
Open access
CTCamille Tron
Camille Tron
FLFlorian Lemaitre
Florian Lemaitre
PBPauline Bros
Pauline Bros
CGClaire Goulvestre
Claire Goulvestre
BFBénédicte Franck
Bénédicte Franck
Benoit BlanchetBenoit Blanchet
Benoit Blanchet
Background: This study compared the performance of plasma infliximab and adalimumab quantification using a commercially available kit (mAbXmise kit) and mass spectrometry readout to that of two ELI...